[
  {
    "ts": null,
    "headline": "Artisan Mid Cap Fund Q2 2025 Commentary",
    "summary": "Artisan Mid Cap Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=95878696f52a58f98a8b30028fb702fafb40eca96f335aff4d82d32857c23c16",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755126900,
      "headline": "Artisan Mid Cap Fund Q2 2025 Commentary",
      "id": 136342844,
      "image": "",
      "related": "DXCM",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=95878696f52a58f98a8b30028fb702fafb40eca96f335aff4d82d32857c23c16"
    }
  },
  {
    "ts": null,
    "headline": "FriskaAi and Dexcom Enter CGM Data Integration Agreement",
    "summary": "ARLINGTON, VA / ACCESS Newswire / August 13, 2025 /FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the ...",
    "url": "https://finnhub.io/api/news?id=919f9fdf3c6a3e853355e74aa9ab80aa2b8b10b6b1d0e4d00cb70022e7f4f4fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091800,
      "headline": "FriskaAi and Dexcom Enter CGM Data Integration Agreement",
      "id": 136328724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "ARLINGTON, VA / ACCESS Newswire / August 13, 2025 /FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the ...",
      "url": "https://finnhub.io/api/news?id=919f9fdf3c6a3e853355e74aa9ab80aa2b8b10b6b1d0e4d00cb70022e7f4f4fd"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk",
    "summary": "The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic,",
    "url": "https://finnhub.io/api/news?id=92d62bc86b044c77c5956389ca3b7d2e7db0d76d63805376bc0ed89cee489570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091260,
      "headline": "Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk",
      "id": 136328297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic,",
      "url": "https://finnhub.io/api/news?id=92d62bc86b044c77c5956389ca3b7d2e7db0d76d63805376bc0ed89cee489570"
    }
  },
  {
    "ts": null,
    "headline": "DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook",
    "summary": "Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=c763dc20f7926ddd0f5b55b9076f1e69d445c71d46d55ad7d897bdd9d75a4d86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057920,
      "headline": "DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook",
      "id": 136328726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=c763dc20f7926ddd0f5b55b9076f1e69d445c71d46d55ad7d897bdd9d75a4d86"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call",
    "summary": "DexCom’s second quarter 2025 results saw the company surpass Wall Street’s revenue and earnings expectations, though the market’s immediate reaction was notably negative. Management attributed the quarter’s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom’s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbur",
    "url": "https://finnhub.io/api/news?id=8fbfe0897883b5eae0e97d27d07b197aa9581beb96d05ac2e053d44794db6ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755056283,
      "headline": "5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call",
      "id": 136328727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom’s second quarter 2025 results saw the company surpass Wall Street’s revenue and earnings expectations, though the market’s immediate reaction was notably negative. Management attributed the quarter’s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom’s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbur",
      "url": "https://finnhub.io/api/news?id=8fbfe0897883b5eae0e97d27d07b197aa9581beb96d05ac2e053d44794db6ab0"
    }
  }
]